VEGFA and metastatic neoplasm: Recognition of this role for VEGF represented the driver for the Phase III AVAST-M adjuvant clinical trial [11], which tested the hypothesis that VEGF-driven angiogenesis is required for progression of micro-metastases to metastatic disease.